Tango Therapeutics
Yahoo Finance • 20 days ago
Tango Appoints Robert Azelby To Board Of Directors
(RTTNews) - Tango Therapeutics, Inc. (TNGX), a clinical-stage biotechnology company, announced the appointment of Robert Azelby to its Board of Directors. Azelby brings more than 30 years of experience in executive management, commercial... Full story
Yahoo Finance • last month
Tango Therapeutics prices upsized $600M public offering at $30/share
Tango Therapeutics (TNGX [https://seekingalpha.com/symbol/TNGX]) announced the pricing [https://seekingalpha.com/pr/20546196-tango-therapeutics-announces-pricing-of-600-million-upsized-public-offering] of an upsized underwritten public off... Full story
Yahoo Finance • last month
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced toda... Full story
Yahoo Finance • last month
Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK
The targeted oncology sector is shifting after GSK (GSK [https://seekingalpha.com/symbol/GSK]) decided to buy [https://seekingalpha.com/news/4601644-gsk-to-buy-nuvalent-for-106b] Nuvalent (NUVL [https://seekingalpha.com/symbol/NUVL]) for $... Full story
Yahoo Finance • last month
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • last month
Pre-Market Movers: TNGX, WOK, GOCO Set The Path
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday, hinting at possible breakout opportunities. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. Price swings ahead of t... Full story
Yahoo Finance • last month
Tango Therapeutics (TNGX) Could Benefit From Pancreatic Ductal Adenocarcinoma Data Announcement
Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 15, the price target on Tango Therapeutics Inc. (NASDAQ:TNGX) was increased from $28 to $55 by Leerink. Follo... Full story
Yahoo Finance • last month
Here is Why Erasca (ERAS) is One of the Best Growth Stocks Under $20
Erasca Inc. (NASDAQ:ERAS) is one of the best growth stocks under $20 to buy. On May 11, Erasca reported positive progress for its precision oncology pipeline, highlighting monotherapy efficacy and a favorable safety profile for its lead ca... Full story
Yahoo Finance • 2 months ago
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
On May 15, 2026, Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals(NASDAQ:CRVS), acquiring 1,100,000 shares in the first quarter for an estimated $17.55 million based on quarterly average pricing. What happened... Full story
Yahoo Finance • 2 months ago
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally
Boxer Capital Management increased its stake in Kodiak Sciences(NASDAQ:KOD) during the first quarter, adding 225,000 shares in a transaction estimated at $5.81 million based on quarterly average pricing, according to a May 15, 2026, SEC fi... Full story
Yahoo Finance • 2 months ago
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
On May 15, 2026, Boxer Capital Management disclosed a purchase of 1,241,000 Vir Biotechnology(NASDAQ:VIR) shares, an estimated $9.89 million trade based on quarterly average pricing. What happened According to a Securities and Exchange C... Full story
Yahoo Finance • 2 months ago
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
What happened According to an SEC filing dated May 15, 2026, Acuta Capital Partners, LLC initiated a new position in Erasca(NASDAQ:ERAS) during the first quarter. The fund acquired 354,575 shares, with an estimated transaction value of $4... Full story
Yahoo Finance • 2 months ago
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points BOSTON, May 13, 2026 (GLOBE NEWSWI... Full story
Yahoo Finance • 2 months ago
Stifel Remains Bullish on Tango Therapeutics (TNGX)
Tango Therapeutics, Inc. (NASDAQ:TNGX) is one of the best performing healthcare stocks so far in 2026. Stifel lifted the price target on Tango Therapeutics, Inc. (NASDAQ:TNGX) to $40 from $24 on April 27, maintaining a Buy rating on the sh... Full story
Yahoo Finance • 2 months ago
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that effective May 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted (i) a non-qualified stock option t... Full story
Yahoo Finance • 3 months ago
Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets
Crystal Adam, President of R&D at Tango Therapeutics(NASDAQ:TNGX), reported the exercise of 27,000 stock options -- with the underlying common shares immediately sold for approximately $572,000 -- according to an SEC Form 4 filing on April... Full story
Yahoo Finance • 3 months ago
Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge
Key Points Adam Crystal sold 20,251 shares for a transaction value of ~$304,000 on March 5, 2026, at an average price of around $15 per share. This sale represented 15.24% of Crystal's direct holdings, reducing his directly held position... Full story
Yahoo Finance • 4 months ago
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary — Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financi... Full story
Yahoo Finance • 4 months ago
Wedbush Reaffirms Outperform Rating for Tango Therapeutics (TNGX)
Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On March 6, Wedbush increased the firm’s price target on Tango Therapeutics Inc. (NASDAQ:TNGX) from $15 to $19 following t... Full story
Yahoo Finance • 4 months ago
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing
On February 17, 2026, Boxer Capital Management, LLC disclosed a buy of 135,000 shares of Celcuity(NASDAQ:CELC), an estimated $11.10 million trade based on quarterly average pricing. What Happened According to a February 17, 2026, SEC fil... Full story